Publicacións en colaboración con investigadores/as de University of Texas Southwestern Medical Center (9)

2024

  1. Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey

    Orphanet Journal of Rare Diseases, Vol. 19, Núm. 1

  2. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment

    Endocrine Practice, Vol. 30, Núm. 9, pp. 810-816

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

2021

  1. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227

2019

  1. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2017

  1. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 377, Núm. 13, pp. 1228-1239

  2. Estimating the prevalence of generalized and partial lipodystrophy: Findings and challenges

    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 10, pp. 375-383

2016

  1. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline

    Journal of Clinical Endocrinology and Metabolism, Vol. 101, Núm. 12, pp. 4500-4511

2015

  1. Ghrelin

    Molecular Metabolism, Vol. 4, Núm. 6, pp. 437-460